Levilimab (BCD-089) is an original human anti-IL-6 receptor monoclonal antibody with optimized constant domain. Levilimab has received fast-track approval in Russia for the treatment of patients with moderate to severe COVID-19 with acute respiratory distress syndrome and severe cytokine release syndrome.

Levilimab is also being developed for the treatment of active rheumatoid arthritis.